206 results on '"Siccardi, Marco"'
Search Results
2. Physiologically‐based pharmacokinetic modelling of long‐acting injectable cabotegravir and rilpivirine in pregnancy
3. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
4. Data Analysis and Phase Ambiguity Removal in the ACES Microwave Link
5. Genetic determinants of key antiretroviral pharmacokinetics
6. Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans.
7. Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies
8. Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling
9. PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease
10. Association of a Single-Nucleotide Polymorphism in the Pregnane X Receptor (PXR 63396C→T) with Reduced Concentrations of Unboosted Atazanavir
11. Ceftriaxone bone penetration in patients with septic non-union of the tibia
12. Can the Dynamic External Pelvimetry Test in Late Pregnancy Reveal Obstructed and Prolonged Labor? Results From a Pilot Study
13. Physiologically based pharmacokinetic modeling for dose optimization of quinine–phenobarbital coadministration in patients with cerebral malaria
14. Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz
15. Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults
16. LONG-ACTING DRUGS AND FORMULATIONS FOR THE TREATMENT AND PREVENTION OF HIV
17. Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma
18. Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling
19. Dynamic External Pelvimetry Test in Third Trimester Pregnant Women: Shifting Positions Affect Pelvic Biomechanics and Create More Room in Obstetric Diameters
20. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C(right arrow)T) with reduced concentrations of unboosted atazanavir
21. Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using PBPK modelling
22. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
23. Physiologically based pharmacokinetic modeling for dose optimization of quinine–phenobarbital coadministration in patients with cerebral malaria.
24. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics
25. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices
26. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling
27. Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation
28. Estimating the Mobility of the Michaelis Sacral Rhombus in Pregnant Women
29. A Postural Approach to the Pelvic Diameters of Obstetrics: The Dynamic External Pelvimetry Test
30. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations
31. Unexpected drug–drug interaction between tipranavir/ritonavir and enfuvirtide
32. Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV‐infected patients: a population PK approach
33. CYP2B6 variants alter etonogestrel pharmacokinetics when combined with efavirenz
34. Analysis of clinical drug-drug interaction data to predict uncharacterized interaction magnitudes between antiretroviral drugs and co-medications
35. A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab
36. Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics
37. Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations
38. Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection
39. Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation.
40. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens
41. Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies
42. Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications
43. Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding
44. Validation of Computational Approaches for Antiretroviral Dose Optimization (vol 60, pg 3838, 2016)
45. Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates
46. In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line
47. Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate
48. Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro
49. Erratum for Siccardi et al., Validation of Computational Approaches for Antiretroviral Dose Optimization
50. Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico , In Vitro , and In Vivo Investigation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.